Learn about the latest treatments for metastatic uterine cancer. We’ve got it covered, from new FDA approvals to emerging approaches in targeted therapy, CAR T-cell therapy, other immunotherapies, drug combinations, and more.

  • April 12, 2021 

    Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial CancerBookmark

    George Lundberg, MD

    The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.

    .

  • October 22, 2020 

    ESMO 2019: Immunotherapy in Cervical and Endometrial CancersBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Contributing Editor George Lundberg, MD, who notes: 

    Recent clinical trial results show that immunotherapy—a type of treatment that boosts the immune system to fight cancer—provided long-lasting, improved outcomes for patients with advanced cervical or endometrial cancer. These are important findings for difficult-to-treat cancers.

    .

  • October 22, 2020 

    Cervical Cancer—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD.

    Cervical cancer can be detected early, but when it is fully developed it requires advanced treatment approaches. This comprehensive review outlines treatment options. (Free registration required, written with a physician audience in mind.)

    .

  • August 7, 2020 

    FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

    George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Pembrolizumab Plus Lenvatinib Approved for Endometrial CancerBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
Emma has been wonderful. She has been in touch regularly.

Elise
Ovarian cancer patient

Some of the most promising new treatments for metastatic uterine cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • October 8, 2020 

    Preliminary Results of Two Large Immune Therapy Studies Show Promise in Advanced Cervical CancerBookmark

    George Lundberg, MD

    Press release from Ohio State University Wexner Medical Center curated by Contributing Editor George Lundberg, MD.

    This press release outlines promising preliminary results from two phase 2 clinical trials testing the drug balstilimab alone or in combination with zalifrelimab.

    .

  • August 26, 2019 

    CAR T-cell Therapy for HPV-Induced Metastatic Cervical CancerBookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

    CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.

    Go to full article published by the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
What if your doctor could know what everyone collectively knew?

Marty Tenenbaum, PhD
Founder of Cancer Commons

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • October 14, 2019 

    Pediatric Palliative Care: A Specialty Comes of Age

    Sarah Friebert, MD

    For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a serious illness can benefit from palliative care, no matter their long-term outlook. Because of its importance for children with cancer, we are honored to… Read more »

  • February 11, 2020 

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 7, 2019 

    Emphasizing Oncogeriatrics

    With: Nicolò Matteo Luca Battisti, MD

    A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International Society of Geriatric Oncology (SIOG); nicolo.battisti@gmail.com Q: Everyone knows that the practice of pediatric oncology is very different from adult oncology. How does the growing field of oncogeriatrics differ from usual adult oncology? A:… Read more »

  • December 3, 2018 

    Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer

    With: Val Jones, MD

    A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical medicine and rehabilitation (PM&R). What do you find to be the best uses of PM&R in patients with cancer at your facility? A: Rehabilitation medicine is one of the best-kept secrets in healthcare. Although the… Read more »

  • September 14, 2018 

    Huge Progress in Palliative Care

    With: Diane E. Meier, MD, FACP

    A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY; diane.meier@mssm.edu Originally published November 8, 2017 Q: You wrote in MedGenMed in 2007 that palliative care was the job of all hospitals. In October 2017 you were honored at the National Academy of Medicine for… Read more »

  • July 23, 2018 

    Cancer Pain and the Opioid Epidemic

    George Lundberg, MD

    A Q&A with Kevin Sevarino, MD, PhD, President-elect of the American Academy of Addiction Psychiatry and Consulting Psychiatrist at Gaylord Hospital in Wallingford, CT Q: Opioid abuse, addiction, and overdose are huge American problems right now. Many cancer patents experience chronic pain. What is the best way to use opioids to manage chronic pain? [Note: The views expressed below represent the opinion of the author,… Read more »

    • Show More

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • April 7, 2021 

    Rankings of Most Common and Deadly Cancer Types Will Shift Over Next Two Decades

    In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research led by Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, as well as the Pancreatic Cancer Action Network (PanCAN) in collaboration with The University of Texas MD Anderson Cancer Center. Published today in JAMA Network Open,… Read more »

  • March 29, 2021 

    Can Really Big Data Inform Precise Decisions for Individual Patients?

    With: Matvey B. Palchuk, MD, MS, FAMIA

    New technologies are transforming cancer research. By optimizing research protocols and leveraging data more efficiently and intelligently, these tools hold the promise to improve personalized cancer care. Here, our Curious Dr. George asks Matvey B. Palchuk, MD, MS, FAMIA, VP of Informatics at TriNetX, LLC, about the capabilities of his company’s platform. Curious Dr. George: Translational medicine has evolved to include personalized medicine and… Read more »

  • November 10, 2020 

    How to Learn About Cancer in a Classroom: Shaping Compassionate Doctors

    With: Marin Langlieb

    The patients and caregivers we serve here at Cancer Commons rely on their doctors to provide expert, compassionate care. Building the skills to give such care can begin early in a doctor’s education. Here, for a change of pace, our Curious Dr. George asks a future doctor about a unique experience that helped her learn how to connect with cancer patients. Marin Langlieb is… Read more »

  • September 9, 2020 

    Is Cancer the Best Way to Die?

    With: Richard Smith, CBE, FMedSci

    In 2014, the prestigious medical research journal The BMJ published a controversial piece called “Dying of cancer is the best death.” Here, our Curious Dr. George asks the author of that piece, Richard Smith, CBE, FMedSci, if and how his thoughts on death have since evolved. Dr. Smith was Editor of The BMJ from 1991 to 2004 and is currently Chair of the Lancet Commission… Read more »

  • August 21, 2020 

    The Power of Precision Medicine is Exemplified by Tempus

    With: Nike Beaubier, MDNamratha Sastry, PhD

    Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.

  • June 29, 2020 

    Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

    Lola Rahib, PhD

    Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

    In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

    Go to full article published by ASCO Daily News.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.